H. Lee Moffitt Cancer Center & Research Institute Licenses Rosetta Resolver® Gene Expression Analysis System

SEATTLE, Wash., and TAMPA, Fla., December 4, 2006 – Rosetta Biosoftware announced today that the H. Lee Moffitt Cancer Center & Research Institute licensed the Rosetta Resolver® system. The Resolver system will be used to add support for collaborations and data exchange, and to analyze gene expression data generated by the Institute’s Total Cancer Care program for discovery of biomarkers that will advance the future of cancer research.

“Moffitt supports state-of-the-art research for preventing cancer and developing cures,” said Timothy Yeatman, M.D., Ph.D., associate center director for Translational Research at the Institute. “The Resolver system will provide us with data management and analysis features necessary for understanding patient response to cancer treatment and thereby help us continue to deliver the top-notch cancer care for our patients for which we are recognized.”

“We are proud to contribute to a process that enables cancer patients, along with their physicians, to make more informed decisions on optimal cancer treatment regimens,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida on the University of South Florida campus, H. Lee Moffitt Cancer Center & Research Institute (www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 16 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of America’s Best Hospitals for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, and applies Rosetta Biosoftware’s proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and Sanofi-Aventis, as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

Editorial Contact:
For Rosetta Biosoftware:
Sasha Paegle
+1.206.926.1292

For H. Lee Moffitt Cancer Center & Research Institute:
Michelle Foley
+1.813.745.1505